Boston Society Gene and Cell Therapy Conference
March 20 - 21, 2025Bristol-Myers Squibb, 250 Water Street, Cambridge, MA 02141 |
In Partnership with:
|
Confirmed Speakers
 |
Keynote Lecture: Bruce L.Levine, PhD Barbara and Edward Netter Professor in Cancer Gene Therapy, Perelman School of Medicine, Univ. of Pennsylvania; Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) Current State of the Cell Therapies & secondary malignancy - title TBA |
 |
Keynote Lecture: Kyle Kolaja, PhD, DABT Fellow, ATS Scientific Vice President, Therapy Area Head, Cell Therapy Safety and Head of Specialty Toxicology Labs at Bristol-Myers Squibb Historical Perspective of Cell Therapies From Discovery to Development and Their Evolution - title TBA |
 |
Jason DelCarpini, PhD Director, Bioanalytical and Molecular Assays @ Moderna Therpeutics Report Harmonization on neutralizing antibodies - title TBA |
 |
Alka Dwivedi, PhD Co-founder of ImmunoACT & Research Fellow @ National Cancer Institute (NCI) India's NextCAR (CAR-T therapy) - title TBA |
 |
Melanie M. Eacho, PhD, RAC Director, Division of Cell Therapy 1, Office of Cellular Therapy and Human Tissue CMC, Office of Therapeutic Products @ FDA/CBER title TBA |
 |
Salvatore Iovino, PhD Sr. Director, Head of Bioanalytical & Biomarker Sciences, Editas Medicine Advanced Bioanalytical Strategies to Determine PK and Biodistribution of Cell and Gene Therapy Products |
 |
Daniel Kirouac, PhD Vice President, Translational & Systems Pharmacology @ Metrum Research Group Systems Modeling, Machine Learning and Engineered-T Cell Pharmacology |
 |
Qingcong Lin, PhD President of Medicilon USA Corp CMC Aspects of ASO Manufacturing
|
 |
Jim McNally, PhD Chief Scientific Officer @ BioAgilytix Bioanalytical Strategies for Cell Therapies: Current Considerations |
 |
Hardik Mody, PhD Principal Scientist, Clinical Pharmacology @ Genentech Clinical Pharmacology Considerations for Autologous & Allogeneic Cell Therapies
|
 |
Mohammed Shadid, PhD, MBA Vice President, Translational Sciences @ Korro Bio Inc. Treating hemophilia and sickle cell disease with cell therapies - title TBA |
 |
Indrajeet Singh, PhD Senior Director, Group Lead, Clinical Pharmacology @ The Janssen Pharmaceutical Companies CARVYKTI - title TBA
|
|
CMC - Panel Discussion |
|||
 |
Andy Liu, PhD VP, Global Head of Individualized and Cell Therapy Development @ Genentech |
 |
Yizhe (Claudia) Chen, PhD Associate Director @ BMS |
2025 Proposed Sessions
Session I: Current State of Cell Therapies
Session II: Emerging Cell therapies
Session III: Bioanalytical Assays
Session IV: Clinical/Quantitative Pharmacology of Cell Therapies
Session V: CMC
Session VI: Lessons Learned from Approved Cell Therapies
Session VII: Regulatory Perspectives
Please Join our LinkedIn Group
